Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Topics Community

Article

Identifying predictors of overall survival among patients with TMB-low metastatic cancer treated with immune checkpoint inhibitors

1 Apr 2025

Abstract excerpt

BACKGROUND: Immune checkpoint inhibitors (ICIs) have significantly advanced cancer therapy, yet their efficacy in tumors with low tumor mutational burden (TMB) remains suboptimal. In this study, we aimed to elucidate the impact of somatic mutations on overall survival (OS) in TMB-low patients treated with ICIs and to explore the potential for personalized treatment selection through machine learning. METHODS: We...

Source

Identifiers

PMID: 40285678
DOI: 10.1093/oncolo/oyaf078

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identifying predictors of overall survival among patients with TMB-low metastatic cancer treated with immune checkpoint inhibitorsPMID 40285678Read ↗

A mutational signature and significantly mutated driver genes associated with immune checkpoint inhibitor response across multiple cancers.Semantic proximity Read ↗

Tumor mutational and indel burden: a systematic pan-cancer evaluation as prognostic biomarkersSemantic proximity Read ↗

Interplay between Tumor Mutational Burden and Mutational Profile and its effect on overall survival: A Post Hoc Analysis of Metastatic Patients Treated with Immune Checkpoint InhibitorsSemantic proximity Read ↗

A mutation-based gene set predicts survival benefit after immunotherapy across multiple cancers and reveals the immune response landscape.Semantic proximity Read ↗

TMBpred: A bioinformatics tool for precise prediction of the Tumor Mutation Burden in 14 cancer typesSemantic proximity Read ↗

Integrated profile of tumor stage and mutational burden predicts disparate clinical responses to immune checkpoint inhibitors: A risk-benefit study.Semantic proximity Read ↗

A Decision-Aid Model for Predicting Triple-Negative Breast Cancer ICI Response Based on Tumor Mutation BurdenSemantic proximity Read ↗

Assessment of Tumor Mutational Burden and Outcomes in Patients With Diverse Advanced Cancers Treated With Immunotherapy.Semantic proximity Read ↗

A Systematic Review and Meta-Analysis of the Impact of Tumour Mutation Burden on Survival Outcomes in Solid TumoursSemantic proximity Read ↗

PD-L1 expression and tumor mutational burden are independent biomarkers in most cancersSemantic proximity Read ↗

Novel tumor mutation score versus tumor mutation burden in predicting survival after immunotherapy in pan-cancer patients from the MSK-IMPACT cohortSemantic proximity Read ↗

Patients deriving long-term benefit from immune checkpoint inhibitors demonstrate conserved patterns of site-specific mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.